Sagimet Biosciences Inc
SGMT
查看详细走势图
6.240USD
-0.040-0.64%
收盘 12/22, 16:00（美东）报价延迟15分钟
202.93M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.64%
5天
+3.48%
1月
-6.45%
6月
-28.44%
今年开始到现在
+38.67%
1年
+26.06%
查看详细走势图
TradingKey Sagimet Biosciences Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Sagimet Biosciences Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名101/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价26.33。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Sagimet Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
10
位分析师
买入
评级
26.333
目标均价
+325.42%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Sagimet Biosciences Inc亮点
亮点风险
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-3.51，处于3年历史合理位
机构减仓
最新机构持股11.98M股，环比减少42.97%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.20M
活跃度降低
近期活跃度降低，过去20天平均换手率-0.37
Sagimet Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Sagimet Biosciences Inc简介
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
公司代码SGMT
公司Sagimet Biosciences Inc
CEOHappel (David)
网址https://sagimet.com/
常见问题
Sagimet Biosciences Inc(SGMT)的当前股价是多少？
Sagimet Biosciences Inc(SGMT)的当前股价是 6.240。
Sagimet Biosciences Inc的股票代码是什么？
Sagimet Biosciences Inc的股票代码是SGMT。
Sagimet Biosciences Inc股票的52周最高点是多少？
Sagimet Biosciences Inc股票的52周最高点是11.410。
Sagimet Biosciences Inc股票的52周最低点是多少？
Sagimet Biosciences Inc股票的52周最低点是1.730。
Sagimet Biosciences Inc的市值是多少？
Sagimet Biosciences Inc的市值是202.93M。
Sagimet Biosciences Inc的净利润是多少？
Sagimet Biosciences Inc的净利润为-45.57M。
现在Sagimet Biosciences Inc(SGMT)的股票是买入、持有还是卖出？
根据分析师评级，Sagimet Biosciences Inc(SGMT)的总体评级为买入，目标价格为26.333。
Sagimet Biosciences Inc(SGMT)股票的每股收益（EPS TTM）是多少
Sagimet Biosciences Inc(SGMT)股票的每股收益（EPS TTM）是-1.792。
相关品种
